Abstract

Human neutrophil elastase (HNE) is a potent serine protease belonging to the chymotrypsin family and is involved in a variety of pathologies affecting the respiratory system. Thus, compounds able to inhibit HNE proteolytic activity could represent effective therapeutics. We present here the synthesis of new thiazol-2-(3H)-ones as an elaboration of potent HNE inhibitors with an isoxazol-5-(2H)-one scaffold that we recently identified. Two-dimensional NMR spectroscopic techniques and tandem mass spectrometry allowed us to correctly assign the structure of the final compounds arising from both tautomers of the thiazol-2-(3H)-one nucleus (N-3 of the thiazol-2-(3H)-one and 3-OH of the thiazole). All new compounds were tested as HNE inhibitors, and no activity was found at the highest concentration used (40 µM), demonstrating that the thiazol-2-(3H)-one is not a good scaffold for HNE inhibitors. Molecular modelling experiments indicate that the low-energy pose might limit the nucleophilic attack on the endocyclic carbonyl group of the thiazolone-based compounds by HNE catalytic Ser195, in contrast to isoxazol-5-(2H)-one analogues.

Highlights

  • Human neutrophil elastase (HNE) is a small, soluble glycoprotein of about 30 kDa belonging to the chymotrypsin family of serine proteases [1] and is expressed primarily in neutrophils, and in monocytes and mast cells [2]

  • HNE performs its proteolytic action through a catalytic triad consisting of Ser195Asp102-His57, where the powerful nucleophile oxygen of Ser195 attacks the carbonyl carbon involved in the peptide bond [4, 5]

  • HNE is involved in a variety of pathologies affecting the respiratory system, such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), acute lung injury (ALI)

Read more

Summary

Introduction

Human neutrophil elastase (HNE) is a small, soluble glycoprotein of about 30 kDa belonging to the chymotrypsin family of serine proteases [1] and is expressed primarily in neutrophils, and in monocytes and mast cells [2]. Our research group is involved in the design and synthesis of small molecules with HNE inhibitory activity, and we have identified a number of new classes of inhibitors based on different bicyclic scaffolds [14–17]. We recently reported new isoxazolone-based derivatives with HNE inhibitory activity in the low nanomolar range ­(IC50 = 20–96 nM) [18]. HNE catalytic residue) and define the endocyclic carbonyl at position 5 of the isoxazolone core as a critical requirement for inhibitory activity [18]. Starting from these results, we report here the development and analytical characterization of a new series of heterocyclic compounds based on the thiazol-2-(3H)-one scaffold originally designed as possible HNE inhibitors (Fig. 2). The first pathway involves carbonyl sulfide loss, which is favored in heterocyclic moieties, followed by a rearrangement and

R1 R2 R4
CH2 R4 N
Results and discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.